Nicox: financing agreement with Soleus

(CercleFinance.com) - Nicox announces that it has entered into a $16.
5 million deal with investment fund Soleus, combining the sale of royalties and equity financing, a transaction that should fund the company until the third quarter of 2025.

Soleus acquired Vyzulta's royalties (net of those paid to Pfizer), for $15 million, and subscribed to shares with warrants (ABSA) at a price of €0.3144 per ABSA, representing an investment of $1.5 million.

In this context, Nicox has also reached an agreement with its main creditor for the release of the security on Vyzulta, providing among other things for the repayment of a debt of 5.2 million euros before the end of June 2025.

In addition, the biopharmaceutical company reports that the acceleration of patient recruitment for the NCX 470 Phase 3 Denali clinical trial means that it can expect to publish the first data as early as the third quarter of 2025.

Copyright (c) 2024 CercleFinance.com. All rights reserved.